Director at PMV Pharmaceuticals (PMVP) granted 42,000 options at $1.19

Rhea-AI Filing Summary

PMV Pharmaceuticals director Charles M. Baum received a grant of stock options covering 42,000 shares of common stock. The options have an exercise price of $1.19 per share and expire on June 4, 2036. They vest on the earlier of June 4, 2027 or the company’s next annual stockholder meeting. Following this award, Baum holds 42,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BAUM CHARLES M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	42,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 42,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 42,000 options Exercise price: $1.19 per share Expiration date: June 4, 2036 +2 more

5 metrics

Options granted 42,000 options Stock Option (right to buy) grant to director

Exercise price $1.19 per share Conversion or exercise price of options

Expiration date June 4, 2036 Option expiration date

Underlying shares 42,000 shares Common stock underlying the options

Post-grant option holdings 42,000 options Total derivative shares following transaction

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 1.1900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"Shares subject to the option vest on the earlier of June 4, 2027 or next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-04T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BAUM CHARLES M

(Last) (First) (Middle)

C/O PMV PHARMACEUTICALS INC.

400 ALEXANDER PARK DRIVE, SUITE 301

(Street)

PRIINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.19	06/04/2026		A		42,000		(1)	06/04/2036	Common Stock	42,000	$0	42,000	D

Explanation of Responses:

1. Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

	/s/ Robert Ticktin, by power of attorney	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did PMV Pharmaceuticals (PMVP) disclose about Charles M. Baum in this filing?

PMV Pharmaceuticals reported that director Charles M. Baum received a grant of stock options for 42,000 shares. These options are a form of equity compensation, giving him the right to buy common stock at a fixed price in the future.

How many stock options did Charles M. Baum receive from PMV Pharmaceuticals (PMVP)?

Charles M. Baum received stock options covering 42,000 shares of PMV Pharmaceuticals common stock. This award increases his potential future ownership if he later exercises the options at the specified exercise price.

What is the exercise price of Charles M. Baum’s PMV Pharmaceuticals (PMVP) stock options?

The stock options granted to Charles M. Baum have an exercise price of $1.19 per share. This means he can buy PMV Pharmaceuticals common stock at $1.19 per share if and when the options are exercised after vesting.

When do Charles M. Baum’s PMV Pharmaceuticals (PMVP) stock options vest?

The options vest on the earlier of June 4, 2027, or the date of PMV Pharmaceuticals’ next annual stockholder meeting. Vesting determines when Baum can begin exercising the options to purchase common shares.

When do the newly granted PMV Pharmaceuticals (PMVP) stock options expire?

The stock options granted to Charles M. Baum expire on June 4, 2036. After that expiration date, he can no longer use these options to buy PMV Pharmaceuticals common stock, even if they were previously vested.

How many PMV Pharmaceuticals (PMVP) options does Charles M. Baum hold after this grant?

Following this grant, Charles M. Baum holds 42,000 stock options directly. This figure represents his position in this specific option award as reported, giving him potential future rights to purchase common shares.